REGIONAL CHEMOTHERAPY TO THE CANINE LIVER WITH 5-FLUOROURACIL (5FU) AND ADRIAMYCIN (AM)

被引：0
|
作者：
KARAKOUSIS, CP [1 ]
SHARMA, SD [1 ]
KANTER, P [1 ]
机构：
[1] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,BUFFALO,NY 14263
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1982年 / 23卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [31] 5-FLUOROURACIL (5FU) PLASMA KINETICS, TUMOR-MARKERS EVOLUTION AND RESPONSE TO CHEMOTHERAPY IN METASTATIC COLORECTAL CANCERS
    GAMELIN, E
    DORVAL, ED
    MAILLART, P
    BURTIN, P
    DUMESNIL, Y
    SCHILLIO, Y
    BACQ, Y
    BOUALI, B
    LARRA, F
    GASTROENTEROLOGY, 1993, 104 (04) : A403 - A403
  • [32] Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor
    Peters, GJ
    van Groeningen, CJ
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4267 - 4268
  • [33] PHARMACOKINETIC PROFILE OF DOXIFLURIDINE (5'-DFUR, FURTULONR), A 5-FLUOROURACIL (5FU) PRO-DRUG
    HEINTZ, RC
    GUNTERT, TW
    SUTTER, C
    LINDERCICCOLUNGHI, SN
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 207 - 207
  • [34] Mechanism for enhanced anti-tumor effects of 5-fluorouracil (5FU) by celecoxib in an advanced colon cancer model: Argiogenesis, or 5FU metabolisms?
    Irie, Takanobu
    Tsujii, Masahiko
    Tsuji, Shingo
    Ishii, Shuji
    Yoshio, Toshiyuki
    Shinzaki, Shinichiro
    Egawa, Satoshi
    Nishida, Tsutomu
    Kakiuchi, Yoshimi
    Yasumaru, Masakazu
    Iijima, Hideki
    Murata, Hiroaki
    Kawano, Sunao
    Hayashi, Norio
    GASTROENTEROLOGY, 2006, 130 (04) : A581 - A581
  • [35] Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin
    Codacci-Pisanelli, G.
    Noordhuis, P.
    van der Wilt, C. L.
    Peters, G. J.
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2008, 27 (6-7): : 733 - 739
  • [36] Corneal Epitheliopathy Following Trabeculectomy With lntraoperative 5-Fluorouracil (5FU) or Mitomycin C (MMC) and Postoperative Adjunctive 5-Fluorouracil in 381 Patients
    Reiter, C.
    Wimmer, S.
    Schultheiss, A.
    Klink, T.
    Grehn, F.
    Geerling, G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [37] Is there a circadian variation in 5-Fluorouracil (5FU) plasma concentration (Cp) given by continuous infusion?
    Strocchi, E
    Camaggi, CM
    Martoni, A
    Sereni, A
    Pannuti, R
    Pittureri, C
    Cacciari, N
    Zamagni, C
    Pannuti, F
    ANNALS OF ONCOLOGY, 1998, 9 : 51 - 51
  • [38] ISOLATED LIVER PERFUSION WITH 5-FLUOROURACIL (5-FU) IN MAN
    AIGNER, K
    WALTHER, H
    TONN, JC
    KRAHL, M
    WENZL, A
    MERKER, G
    SCHWEMMLE, K
    CHIRURG, 1982, 53 (09): : 571 - 573
  • [39] Inhibition of posterior capsular opacification (PCO) in rabbit and monkey eyes with 5-fluorouracil (5FU)
    Lundgren, B
    Andersson, K
    Lundberg, K
    Golander, CG
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 881 - 881
  • [40] Vistonuridine: An orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose
    von Borstel, R.
    O'Neil, J.
    Bamat, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345